Veru (VERU) Releases Earnings Results, Misses Expectations By $0.01 EPS
Veru (NASDAQ:VERU) issued its earnings results on Wednesday. The company reported ($0.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.01), Fidelity Earnings reports. The business had revenue of $6.98 million during the quarter, compared to analyst estimates of $6.98 million. Veru had a negative net margin of 111.10% and a negative return on equity of 60.83%. Veru updated its FY 2019 guidance to EPS.
Shares of VERU traded up $0.07 during mid-day trading on Thursday, hitting $1.65. 300 shares of the company’s stock were exchanged, compared to its average volume of 143,539. The stock has a market capitalization of $99.12 million, a PE ratio of -4.22 and a beta of 0.88. Veru has a fifty-two week low of $1.18 and a fifty-two week high of $2.37. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 1.58.
A number of equities research analysts have recently commented on VERU shares. HC Wainwright reiterated a “buy” rating and issued a $4.50 target price on shares of Veru in a research report on Wednesday, January 23rd. Oppenheimer started coverage on shares of Veru in a research report on Tuesday, March 19th. They issued an “outperform” rating and a $5.00 target price for the company. Zacks Investment Research upgraded shares of Veru from a “sell” rating to a “buy” rating and set a $1.50 target price for the company in a research report on Tuesday, February 19th. CIBC started coverage on shares of Veru in a research report on Wednesday, March 20th. They issued an “outperform” rating and a $5.00 target price for the company. Finally, Maxim Group set a $6.00 target price on shares of Veru and gave the company a “buy” rating in a research report on Thursday, February 14th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.40.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc grew its position in Veru by 1.2% in the 3rd quarter. Vanguard Group Inc now owns 1,199,963 shares of the company’s stock valued at $1,704,000 after buying an additional 13,650 shares during the last quarter. Geode Capital Management LLC grew its position in Veru by 115.4% in the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after buying an additional 115,506 shares during the last quarter. BlackRock Inc. grew its position in Veru by 7.5% in the 1st quarter. BlackRock Inc. now owns 138,404 shares of the company’s stock valued at $202,000 after buying an additional 9,638 shares during the last quarter. Raymond James & Associates grew its position in Veru by 42.0% in the 1st quarter. Raymond James & Associates now owns 125,000 shares of the company’s stock valued at $183,000 after buying an additional 37,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Veru by 328.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 102,909 shares of the company’s stock worth $146,000 after purchasing an additional 78,909 shares in the last quarter. Institutional investors and hedge funds own 8.81% of the company’s stock.
Veru Company Profile
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Article: Golden Cross
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.